IL266428B2 - High-density lipoprotein (HDL) is restored to treat myocardial infarction - Google Patents
High-density lipoprotein (HDL) is restored to treat myocardial infarctionInfo
- Publication number
- IL266428B2 IL266428B2 IL266428A IL26642819A IL266428B2 IL 266428 B2 IL266428 B2 IL 266428B2 IL 266428 A IL266428 A IL 266428A IL 26642819 A IL26642819 A IL 26642819A IL 266428 B2 IL266428 B2 IL 266428B2
- Authority
- IL
- Israel
- Prior art keywords
- csl112
- rhdl
- subjects
- formulation
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662420050P | 2016-11-10 | 2016-11-10 | |
| US201762472240P | 2017-03-16 | 2017-03-16 | |
| PCT/AU2017/051232 WO2018085890A1 (en) | 2016-11-10 | 2017-11-10 | Reconstituted high density lipoprotein treatment of myocardial infarction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL266428A IL266428A (en) | 2019-06-30 |
| IL266428B1 IL266428B1 (en) | 2024-08-01 |
| IL266428B2 true IL266428B2 (en) | 2024-12-01 |
Family
ID=62109053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL266428A IL266428B2 (en) | 2016-11-10 | 2017-11-10 | High-density lipoprotein (HDL) is restored to treat myocardial infarction |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200038481A1 (enExample) |
| EP (1) | EP3538105A4 (enExample) |
| JP (2) | JP2019533705A (enExample) |
| KR (2) | KR20240044543A (enExample) |
| CN (2) | CN116196395A (enExample) |
| AU (2) | AU2017358402B2 (enExample) |
| BR (1) | BR112019007709A2 (enExample) |
| CA (1) | CA3043110A1 (enExample) |
| IL (1) | IL266428B2 (enExample) |
| MX (1) | MX2019005459A (enExample) |
| SG (2) | SG11201903945XA (enExample) |
| WO (1) | WO2018085890A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3373828B1 (en) | 2015-11-09 | 2025-12-10 | Revamp Medical Ltd. | Blood flow reducer for cardiovascular treatment |
| EP3893958B1 (en) | 2018-12-11 | 2026-07-29 | Revamp Medical Ltd. | Systems for adjusting blood flow in a body lumen |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| WO2025210584A1 (en) * | 2024-04-04 | 2025-10-09 | CSL Innovation Pty Ltd | Reconstituted high density lipoprotein treatment of myocardial infarction |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04011312A (es) | 2002-05-17 | 2005-02-14 | Esperion Therapeutics Inc | Metodo para el tratamiento de desordenes dislipidemicos. |
| EP3492085A1 (en) * | 2010-06-30 | 2019-06-05 | CSL Limited | A reconstituted high density lipoprotein formulation and production method therof |
| CN104010646A (zh) | 2011-12-21 | 2014-08-27 | Csl有限公司 | 用于载脂蛋白制剂的剂量方案 |
| US9125943B2 (en) * | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
| EP2853259A1 (en) * | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| WO2016019333A1 (en) * | 2014-07-31 | 2016-02-04 | Kinemed, Inc. | The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties |
-
2017
- 2017-11-10 KR KR1020247010199A patent/KR20240044543A/ko not_active Withdrawn
- 2017-11-10 JP JP2019524144A patent/JP2019533705A/ja active Pending
- 2017-11-10 IL IL266428A patent/IL266428B2/en unknown
- 2017-11-10 BR BR112019007709-0A patent/BR112019007709A2/pt not_active Application Discontinuation
- 2017-11-10 SG SG11201903945XA patent/SG11201903945XA/en unknown
- 2017-11-10 MX MX2019005459A patent/MX2019005459A/es unknown
- 2017-11-10 US US16/348,106 patent/US20200038481A1/en not_active Abandoned
- 2017-11-10 SG SG10201911714YA patent/SG10201911714YA/en unknown
- 2017-11-10 WO PCT/AU2017/051232 patent/WO2018085890A1/en not_active Ceased
- 2017-11-10 EP EP17868674.7A patent/EP3538105A4/en active Pending
- 2017-11-10 CA CA3043110A patent/CA3043110A1/en active Pending
- 2017-11-10 AU AU2017358402A patent/AU2017358402B2/en active Active
- 2017-11-10 CN CN202310189946.6A patent/CN116196395A/zh active Pending
- 2017-11-10 KR KR1020197016627A patent/KR20190084095A/ko not_active Ceased
- 2017-11-10 CN CN201780069271.4A patent/CN109922810A/zh active Pending
-
2022
- 2022-06-01 JP JP2022089334A patent/JP7464654B2/ja active Active
-
2023
- 2023-08-03 US US18/230,058 patent/US20240207357A1/en active Pending
- 2023-12-15 AU AU2023282314A patent/AU2023282314A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019117552A3 (enExample) | 2021-06-25 |
| AU2017358402B2 (en) | 2023-10-05 |
| BR112019007709A2 (pt) | 2019-07-09 |
| RU2019117552A (ru) | 2020-12-10 |
| MX2019005459A (es) | 2019-08-12 |
| SG11201903945XA (en) | 2019-05-30 |
| CN116196395A (zh) | 2023-06-02 |
| JP2022116254A (ja) | 2022-08-09 |
| KR20190084095A (ko) | 2019-07-15 |
| AU2023282314A1 (en) | 2024-01-18 |
| JP2019533705A (ja) | 2019-11-21 |
| EP3538105A4 (en) | 2020-05-20 |
| IL266428A (en) | 2019-06-30 |
| EP3538105A1 (en) | 2019-09-18 |
| SG10201911714YA (en) | 2020-02-27 |
| US20240207357A1 (en) | 2024-06-27 |
| CA3043110A1 (en) | 2018-05-17 |
| CN109922810A (zh) | 2019-06-21 |
| AU2017358402A1 (en) | 2019-04-18 |
| WO2018085890A1 (en) | 2018-05-17 |
| KR20240044543A (ko) | 2024-04-04 |
| IL266428B1 (en) | 2024-08-01 |
| US20200038481A1 (en) | 2020-02-06 |
| JP7464654B2 (ja) | 2024-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240207357A1 (en) | Reconstituted high density lipoprotein treatment of myocardial infarction | |
| Hovingh et al. | The effect of an apolipoprotein AI–containing high-density lipoprotein–mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study | |
| Awan et al. | Inflammation modulation and cardiovascular disease prevention | |
| Lyden et al. | Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers | |
| Bisciglia et al. | Risk factors for ischemic heart disease | |
| US11957731B2 (en) | Reconstituted HDL formulation | |
| Mariano et al. | Dysferlin‐deficient muscular dystrophy and innate immune activation | |
| Ashizuka et al. | Adrenomedullin therapy in patients with refractory ulcerative colitis: a case series | |
| Zubirán et al. | Recent advances in targeted management of inflammation in atherosclerosis: a narrative review | |
| Barter et al. | Targeting high-density lipoproteins to reduce cardiovascular risk: what is the evidence? | |
| Baldassarre et al. | Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment | |
| NZ719724A (en) | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor | |
| Kones et al. | Current treatment of dyslipidemia: evolving roles of non-statin and newer drugs | |
| Kim et al. | Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients | |
| Gagel et al. | What is the optimal low-density lipoprotein cholesterol? | |
| US20160235672A1 (en) | Reconstituted high density lipoproteins composition and uses thereof | |
| RU2798830C2 (ru) | Лечение восстановленным липопротеином высокой плотности инфаркта миокарда | |
| KR20200085292A (ko) | 심장 질병, 심혈관 질병 및 관련 질환 및 증상을 치료하고 그로부터 보호하는 방법 | |
| Candido et al. | Linking diabetes and atherosclerosis | |
| WO2025210584A1 (en) | Reconstituted high density lipoprotein treatment of myocardial infarction | |
| KR20260025091A (ko) | 재조합 조직 플라스미노겐 활성제(tpa) 단편 및 이의 용도 | |
| RU2776110C2 (ru) | Схема дозирования для составов аполипопротеина | |
| Zubirán et al. | Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative | |
| Jackson | Improving prognosis in ischemic heart disease: time to maximize benefit | |
| Sirtori et al. | High density lipoprotein administration: a new therapeutic modality for the treatment of cardiovascular diseases |